Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Recruiting 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 5OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 5

Conditions

Carcinoma, Non-Small-Cell Lung 147Melanoma 122Breast Neoplasms 98Squamous Cell Carcinoma of Head and Neck 96Triple Negative Breast Neoplasms 85Lung Neoplasms 64Neoplasm Metastasis 53Carcinoma, Renal Cell 49Neoplasms 46Head and Neck Neoplasms 46Colorectal Neoplasms 41Ovarian Neoplasms 38Carcinoma, Transitional Cell 37Carcinoma, Hepatocellular 36Pancreatic Neoplasms 35Urinary Bladder Neoplasms 34Recurrence 33Stomach Neoplasms 32Glioblastoma 30Brain Neoplasms 28Sarcoma 26Endometrial Neoplasms 25Prostatic Neoplasms 23Hodgkin Disease 22Uterine Cervical Neoplasms 19Fallopian Tube Neoplasms 19Carcinoma, Squamous Cell 19Esophageal Squamous Cell Carcinoma 17Adenocarcinoma 17Multiple Myeloma 16

Interventions

Mitotane 7Cisplatin 6pembrolizumab 5Etoposide 3Doxorubicin 3camrelizumab 2apatinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Cytoreduction Surgical Procedures 2sodium thiosulfate 1iodophenyl metomidate 1fludarabine phosphate 1dostarlimab 1cemiplimab 1cabozantinib 1cabazitaxel 1antineoplaston AS 2-1 1antineoplaston A10 1Suramin 1Sunitinib 1Streptozocin 1Sorafenib 1Radiation 1Paclitaxel 1Observation 1Nivolumab 1Megestrol Acetate 1Lymph Node Excision 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Adrenocortical Carcinoma × pembrolizumab × Clear all
NCT06066333 2026-04-15

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
12 enrolled
Endocrine

Adrenocortical Carcinoma

NCT02673333 2026-04-06

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
39 enrolled 7 charts
Endocrine

Adrenocortical Carcinoma

NCT06006013 2026-02-18

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Emory University

Phase 2 Recruiting
21 enrolled
Endocrine

Adrenal Cortex Neoplasms, Adrenocortical Carcinoma

NCT05634577 2025-06-19

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
Endocrine

Adrenocortical Carcinoma

NCT05563467 2025-04-02

PEMBR-01

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 2 Recruiting
24 enrolled
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡